Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,589,424
  • Shares Outstanding, K 303,950
  • Annual Sales, $ 15,161 M
  • Annual Income, $ 4,272 M
  • 36-Month Beta 1.22
  • Price/Sales 3.55
  • Price/Cash Flow 7.80
  • Price/Book 1.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 3.67
  • Number of Estimates 8
  • High Estimate 3.84
  • Low Estimate 3.51
  • Prior Year 3.81
  • Growth Rate Est. (year over year) -3.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.61 +7.57%
on 09/07/18
178.33 -0.10%
on 09/18/18
+7.73 (+4.54%)
since 08/17/18
3-Month
156.81 +13.61%
on 06/19/18
178.33 -0.10%
on 09/18/18
+18.10 (+11.31%)
since 06/18/18
52-Week
123.73 +43.98%
on 02/09/18
178.33 -0.10%
on 09/18/18
+22.49 (+14.45%)
since 09/18/17

Most Recent Stories

More News
Company News For Sep 17, 2018

Companies In The News are: ADBE,LB,NI,SHPG

LB : 29.57 (+3.97%)
ADBE : 270.79 (+0.95%)
SHPG : 178.15 (+1.04%)
NI : 25.92 (+0.74%)
Shire Announces The Pricing Terms And Increase In The Maximum Tender Amount Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), and Shire Acquisitions Investments Ireland DAC, an Irish...

BXLT : 46.02 (-0.39%)
SHPG : 178.15 (+1.04%)
Shire's ADHD Portfolio Remains Strong Amid Competition

Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

JNJ : 140.54 (+0.41%)
NVS : 85.03 (-0.12%)
SHPG : 178.15 (+1.04%)
GILD : 73.67 (+1.22%)
Shire Announces Early Results Of The Previously Announced Cash Tender Offers For Certain Outstanding Notes

Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), and Shire Acquisitions Investments Ireland DAC, an Irish...

BXLT : 46.02 (-0.39%)
SHPG : 178.15 (+1.04%)
SHIRE ANNOUNCES EARLY RESULTS OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES

SHIRE ANNOUNCES EARLY RESULTS OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES

BXLT : 46.02 (-0.39%)
SHPG : 178.15 (+1.04%)
Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise

Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise

SHPG : 178.15 (+1.04%)
Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema

Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same....

LGND : 265.72 (+4.75%)
CELG : 87.61 (+0.47%)
SHPG : 178.15 (+1.04%)
GILD : 73.67 (+1.22%)
SHIRE ANNOUNCES CASH TENDER OFFERS FOR UP TO $2,250,000,000 OUTSTANDING PRINCIPAL AMOUNT OF NOTES

SHPG : 178.15 (+1.04%)
Shire Announces FDA Approval of TAKHZYRO(TM) (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

Shire Announces FDA Approval of TAKHZYRO(TM) (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

SHPG : 178.15 (+1.04%)
Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

JNJ : 140.54 (+0.41%)
SHPG : 178.15 (+1.04%)
GILD : 73.67 (+1.22%)
PFE : 43.51 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade SHPG with:

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Key Turning Points

2nd Resistance Point 179.60
1st Resistance Point 178.88
Last Price 178.15
1st Support Level 176.88
2nd Support Level 175.60

See More

52-Week High 178.33
Last Price 178.15
Fibonacci 61.8% 157.47
Fibonacci 50% 151.03
Fibonacci 38.2% 144.59
52-Week Low 123.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar